Literature DB >> 19729487

Vascular permeability and pathological angiogenesis in caveolin-1-null mice.

Sung-Hee Chang1, Dian Feng, Janice A Nagy, Tracey E Sciuto, Ann M Dvorak, Harold F Dvorak.   

Abstract

Caveolin-1, the signature protein of endothelial cell caveolae, has many important functions in vascular cells. Caveolae are thought to be the transcellular pathway by which plasma proteins cross normal capillary endothelium, but, unexpectedly, cav-1(-/-) mice, which lack caveolae, have increased permeability to plasma albumin. The acute increase in vascular permeability induced by agents such as vascular endothelial growth factor (VEGF)-A occurs through venules, not capillaries, and particularly through the vesiculo-vacuolar organelle (VVO), a unique structure composed of numerous interconnecting vesicles and vacuoles that together span the venular endothelium from lumen to ablumen. Furthermore, the hyperpermeable blood vessels found in pathological angiogenesis, mother vessels, are derived from venules. The present experiments made use of cav-1(-/-) mice to investigate the relationship between caveolae and VVOs and the roles of caveolin-1 in VVO structure in the acute vascular hyperpermeability induced by VEGF-A and in pathological angiogenesis and associated chronic vascular hyperpermeability. We found that VVOs expressed caveolin-1 variably but, in contrast to caveolae, were present in normal numbers and with apparently unaltered structure in cav-1(-/-) mice. Nonetheless, VEGF-A-induced hyperpermeability was strikingly reduced in cav-1(-/-) mice, as was pathological angiogenesis and associated chronic vascular hyperpermeability, whether induced by VEGF-A(164) or by a tumor. Thus, caveolin-1 is not necessary for VVO structure but may have important roles in regulating VVO function in acute vascular hyperpermeability and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729487      PMCID: PMC2751571          DOI: 10.2353/ajpath.2009.090171

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  57 in total

1.  Knockdown of caveolin-1 by antisense oligonucleotides impairs angiogenesis in vitro and in vivo.

Authors:  C Griffoni; E Spisni; S Santi; M Riccio; T Guarnieri; V Tomasi
Journal:  Biochem Biophys Res Commun       Date:  2000-09-24       Impact factor: 3.575

2.  Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice.

Authors:  M Drab; P Verkade; M Elger; M Kasper; M Lohn; B Lauterbach; J Menne; C Lindschau; F Mende; F C Luft; A Schedl; H Haller; T V Kurzchalia
Journal:  Science       Date:  2001-08-09       Impact factor: 47.728

3.  Different pathways of macromolecule extravasation from hyperpermeable tumor vessels.

Authors:  D Feng; J A Nagy; A M Dvorak; H F Dvorak
Journal:  Microvasc Res       Date:  2000-01       Impact factor: 3.514

Review 4.  The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle.

Authors:  A M Dvorak; D Feng
Journal:  J Histochem Cytochem       Date:  2001-04       Impact factor: 2.479

5.  Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities.

Authors:  B Razani; J A Engelman; X B Wang; W Schubert; X L Zhang; C B Marks; F Macaluso; R G Russell; M Li; R G Pestell; D Di Vizio; H Hou; B Kneitz; G Lagaud; G J Christ; W Edelmann; M P Lisanti
Journal:  J Biol Chem       Date:  2001-07-16       Impact factor: 5.157

6.  Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors.

Authors:  D Feng; J A Nagy; R A Brekken; A Pettersson; E J Manseau; K Pyne; R Mulligan; P E Thorpe; H F Dvorak; A M Dvorak
Journal:  J Histochem Cytochem       Date:  2000-04       Impact factor: 2.479

7.  Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice.

Authors:  William Schubert; Philippe G Frank; Scott E Woodman; Hideyuki Hyogo; David E Cohen; Chi-Wing Chow; Michael P Lisanti
Journal:  J Biol Chem       Date:  2002-08-07       Impact factor: 5.157

8.  Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype.

Authors:  David S Park; Scott E Woodman; William Schubert; Alex W Cohen; Philippe G Frank; Madhulika Chandra; Jamshid Shirani; Babak Razani; Baiyu Tang; Linda A Jelicks; Stephen M Factor; Louis M Weiss; Herbert B Tanowitz; Michael P Lisanti
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

9.  Structural modulations of plasmalemmal vesicles.

Authors:  G E Palade; R R Bruns
Journal:  J Cell Biol       Date:  1968-06       Impact factor: 10.539

Review 10.  Endothelial stomatal and fenestral diaphragms in normal vessels and angiogenesis.

Authors:  R V Stan
Journal:  J Cell Mol Med       Date:  2007 Jul-Aug       Impact factor: 5.310

View more
  43 in total

1.  A new role for the muscle repair protein dysferlin in endothelial cell adhesion and angiogenesis.

Authors:  Arpeeta Sharma; Carol Yu; Cleo Leung; Andy Trane; Marco Lau; Soraya Utokaparch; Furquan Shaheen; Nader Sheibani; Pascal Bernatchez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-08-19       Impact factor: 8.311

2.  Role of caveolin-2 in subcutaneous tumor growth and angiogenesis associated with syngeneic mouse Lewis lung carcinoma and B16 melanoma models.

Authors:  Yajun Liu; Grzegorz Sowa
Journal:  Cancer Cell Microenviron       Date:  2014

Review 3.  Tumors: wounds that do not heal-redux.

Authors:  Harold F Dvorak
Journal:  Cancer Immunol Res       Date:  2015-01       Impact factor: 11.151

4.  Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis.

Authors:  Jacky G Goetz; Susana Minguet; Inmaculada Navarro-Lérida; Juan José Lazcano; Rafael Samaniego; Enrique Calvo; Marta Tello; Teresa Osteso-Ibáñez; Teijo Pellinen; Asier Echarri; Ana Cerezo; Andres J P Klein-Szanto; Ricardo Garcia; Patricia J Keely; Paloma Sánchez-Mateos; Edna Cukierman; Miguel A Del Pozo
Journal:  Cell       Date:  2011-07-08       Impact factor: 41.582

5.  Orphan nuclear transcription factor TR3/Nur77 regulates microvessel permeability by targeting endothelial nitric oxide synthase and destabilizing endothelial junctions.

Authors:  Dezheng Zhao; Liuliang Qin; Pierre-Marie Bourbon; Lauralee James; Harold F Dvorak; Huiyan Zeng
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-05       Impact factor: 11.205

6.  Single-chain VEGF/Cy5.5 targeting vegf receptors to indicate atherosclerotic plaque instability.

Authors:  Ming Kai Lam; Sali Al-Ansari; Gooitzen M van Dam; René A Tio; Jan-Cees Breek; Riemer H J A Slart; Jan-Luuk Hillebrands; Clark J Zeebregts
Journal:  Mol Imaging Biol       Date:  2013-06       Impact factor: 3.488

7.  Host deficiency in caveolin-2 inhibits lung carcinoma tumor growth by impairing tumor angiogenesis.

Authors:  Yajun Liu; Sungchan Jang; Leike Xie; Grzegorz Sowa
Journal:  Cancer Res       Date:  2014-09-30       Impact factor: 12.701

Review 8.  Lipids in the cell: organisation regulates function.

Authors:  Ana L Santos; Giulio Preta
Journal:  Cell Mol Life Sci       Date:  2018-02-09       Impact factor: 9.261

9.  Loss of caveolin-1 causes blood-retinal barrier breakdown, venous enlargement, and mural cell alteration.

Authors:  Xiaowu Gu; Steven J Fliesler; You-Yang Zhao; William B Stallcup; Alex W Cohen; Michael H Elliott
Journal:  Am J Pathol       Date:  2013-12-08       Impact factor: 4.307

10.  Nucleoside diphosphate kinase B regulates angiogenic responses in the endothelium via caveolae formation and c-Src-mediated caveolin-1 phosphorylation.

Authors:  Shalini Gross; Kavi Devraj; Yuxi Feng; Jadranka Macas; Stefan Liebner; Thomas Wieland
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.